Northeast Investment Management lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 214,150 shares of the company’s stock after selling 4,006 shares during the period. Johnson & Johnson accounts for about 2.0% of Northeast Investment Management’s portfolio, making the stock its 16th largest position. Northeast Investment Management’s holdings in Johnson & Johnson were worth $35,446,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in JNJ. Atlantic Private Wealth LLC bought a new position in Johnson & Johnson in the first quarter valued at about $32,000. 25 LLC bought a new position in Johnson & Johnson in the first quarter valued at about $55,000. Horizons Wealth Management boosted its holdings in Johnson & Johnson by 1,730.0% in the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after acquiring an additional 346 shares during the last quarter. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the second quarter valued at about $66,000. Finally, Sanctuary Wealth Management L.L.C. bought a new position in Johnson & Johnson in the second quarter valued at about $109,000. Institutional investors own 68.40% of the company’s stock.
Johnson & Johnson Stock Up 0.4 %
Shares of Johnson & Johnson stock opened at $153.00 on Monday. The business’s 50 day simple moving average is $161.23 and its 200 day simple moving average is $162.45. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The firm has a market cap of $397.64 billion, a PE ratio of 11.36, a P/E/G ratio of 3.09 and a beta of 0.55. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Monday, November 20th. Johnson & Johnson’s dividend payout ratio is presently 35.34%.
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Analyst Ratings Changes
Several research firms recently issued reports on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 18th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 18th. Credit Suisse Group raised their target price on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Barclays raised their target price on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday, October 12th. Finally, Wells Fargo & Company reduced their target price on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a report on Thursday, August 31st. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $169.19.
View Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- What Are Dividend Challengers?
- Bargain Alert: Crocs a Footwear Brand With Single Digit P/E Ratio
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- MarketBeat Week in Review – 10/16 – 10/20
- Why Consider Investing in Nanotechnology Stocks
- Institutions Buy Consumer Staples, is the Bottom in?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
